Transcriptional gene silencing as a genetic therapy for HIV-1

Future HIV Therapy

Volumn 2, Issue 4, 2008, Pages 339-349

  Turner, Anne Marie W ^a   Morris, Kevin V ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Epigenetics; Gene silencing; Genetic therapy; HIV 1; RNA; Small RNA; Transcription

Indexed keywords

ADENOVIRUS VECTOR; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; ARGONAUTE 2 PROTEIN; COMPLEMENTARY RNA; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LENTIVIRUS VECTOR; NEF PROTEIN; PLACEBO; POL PROTEIN; RETROVIRUS VECTOR; SHORT HAIRPIN RNA; SMALL INTERFERING RNA;

CARCINOGENESIS; DNA METHYLATION; DRUG SAFETY; DRUG TARGETING; GENE SILENCING; GENE THERAPY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERMINAL REPEAT; MURINE LEUKEMIA VIRUS; NONHUMAN; PATIENT COMPLIANCE; POSTTRANSCRIPTIONAL GENE SILENCING; PROMOTER REGION; REVIEW; RNA INTERFERENCE; T CELL LEUKEMIA; VIRAL GENE DELIVERY SYSTEM; VIRUS GENOME; VIRUS LATENCY; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS TRANSCRIPTION;

EID: 52649176737     PISSN: 17469600     EISSN: None     Source Type: Journal    
DOI: 10.2217/17469600.2.4.339     Document Type: Review

References (123)

1. UNAIDS, AIDS Epidemic Update: December 2007, 1-60 (2007).
2. Chen LFLF, Hoy JJ, Lewin SRSR: Ten years of highly active antiretroviral therapy for HIV infection. Med. J. Aust. 186, 146-151 (2007).
3. Hofman P, Nelson AM: The pathology induced by highly active antiretroviral therapy against human immunodeficiency virus: an update. Curr. Med. Chem. 13, 3121-3132 (2006).
4. Levy AR, James D, Johnston KM et al.: The direct costs of HIV/AIDS care. Lancet Infect. Dis 6, 171-177 (2006).
5. Lamourelle G, Harrison P, Rowley J, Warren M: Tracking funding for preventive HIV vaccine research & development: estimates of annual investments and expenditures 2000-2005. International AIDS Vaccine Initiative 1-21 (2005).
6. Berkley SF, Koff WC: Scientific and policy challenges to development of an AIDS vaccine. Lancet 370, 94-101 (2007).
7. Cohen J: AIDS research: promising AIDS vaccine's failure leaves field reeling. Science 318, 28-29 (2007).
8. Dropulic B, June CH: Gene-based immunotherapy for human immunodeficiency virus infection and acquired immunodeficiency syndrome. Hum. Gene Ther. 17, 577-588 (2006).
9. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391, 806-811 (1998).
10. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494-498 (2001).
11. Lee Y, Ahn C, Han JJ et al.: The nuclear RNase III Drosha initiates microRNA processing. Nature 425, 415-419 (2003).
12. Lund E, Guttinger S, Calado A, Dahlberg JE, Kutay U: Nuclear export of microRNA precursors. Science 303, 95-98 (2004).
13. Bernstein E, Caudy AA, Hammond SM, Hannon GJ: Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 409, 363-366 (2001).
14. Chendrimada TP, Gregory RI, Kumaraswamy E et al.: TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature 436, 740-744 (2005).
15. Lee Y, Hur I, Park S-Y, Kim Y-K, Suh MR, Kim VN: The role of PACT in the RNA silencing pathway. EMBO J. 25, 522-632 (2006).
16. Hammond SM, Boettcher S, Caudy AA, Kobayashi R, Hannon GJ: Argonaute2, a link between genetic and biochemical analyses of RNAi. Science 293, 1146-1150 (2001).
17. Liu JD, Carmell MA, Rivas FV et al.: Argonaute2 is the catalytic engine of mammalian RNAi. Science 305, 1437-1441 (2004).
18. Meister G, Landthaler M, Patkaniowska A, Dorsett Y, Teng G, Tuschl T: Human argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. Mol. Cell 15, 185-197 (2004).
19. Rand TA, Petersen S, Du F, Wang X: Argonaute2 cleaves the anti-guide strand of siRNA during RISC activation. Cell 123, 621-629 (2005).
20. Song J-J, Smith SK, Hannon GJ, Joshua-Tor L: Crystal structure of argonaute and its implications for RISC slicer activity. Science 305, 1434-1437 (2004).
21. Matranga C, Tomari Y, Shin C, Bartel DP, Zamore PD: Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes. Cell 123, 607-620 (2005).
22. Ambros V: The functions of animal microRNAs, Nature 431, 350-355 (2004).
23. Lee NS, Rossi JJ: Control of HIV-1 replication by RNA interference. Virus Res. 102, 53-58 (2004).
24. Jacque JM, Triques K, Stevenson M: Modulation of HIV-1 replication by RNA interference. Nature 418, 435-438 (2002).
25. Westerhout E, ter Brake O, Berkhout B: The virion-associated incoming HIV-1 RNA genome is not targeted by RNA interference. Retrovirology 3, 57 (2006).
26. Capodici J, Kariko K, Weissman D: Inhibition of HIV-1 infection by small interfering RNA-mediated RNA interference. J. Immunol. 169, 5196-5201 (2002).
27. Hu W-Y, Myers CP, Kilzer JM, Pfaff SL, Bushman FD: Inhibition of retroviral pathogenesis by RNA interference. Curr. Biol. 12, 1301-1311 (2002).
28. Surabhi RM, Gaynor RB: RNA interference directed agains viral and cellular targets inhibits human immunodeficiency virus type 1 replication. J. Virol. 76, 12963-12973 (2002).
29. Coburn GA, Cullen BR: Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference. J. Virol. 76, 9225-9231 (2002).
30. Morris KV, Chung CH, Witke W, Looney DJ: Inhibition of HIV-1 replication by siRNA targeting conserved regions of gag/pol. RNA Biol. 2, 17-20 (2005).
31. Novina CD, Murray MF, Dykxhoorn DM et al.: siRNA-directed inhibition of HIV-1 infection. Nat. Med. 8, 681-686 (2002).
32. Lee NS, Dohjima T, Bauer G et al.: Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat. Biotechnol. 20, 500-505 (2002).
33. Boden D, Pusch O, Lee F, Tucker L, Ramratnam B: Human immunodeficiency virus type 1 escape from RNA interference. J. Virol. 77, 11531-11535 (2003).
34. Das AT, Brummelkamp TR, Westerhout EM et al.: Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J. Virol. 78, 2601-2605 (2004).
35. Westerhout EM, Ooms M, Vink M, Das AT, Berkhout B: HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome. Nucleic Acids Res. 33, 796-804 (2005).
36. Konstantinova P, de Vries W, Haasnoot J, ter Brake O, de Haan P, Berkhout B: Inhibition of human immunodeficiency virus type 1 by RNA interference using long-hairpin RNA. Gene Ther. 13, 1403-1413 (2006).
37. Akashi H, Miyagishi M, Yokota T et al.: Escape from the interferon response associated with RNA interference using vectors that encode long modified hairpin-RNA. Mol. Biosyst. 1, 382-390 (2005).
38. Barichievy S, Saayman S, von Elje KJ, Morris KV, Arbuthnot P, Weinberg MS: The inhibitory efficacy of RNA POL III-expressed long hairpin RNAs targeted to untranslated regions of the HIV-15′ long terminal repeat. Oligonucleotides 17, 419-432 (2007).
39. Liu YP, Haasnoot J, Berkhout B: Design of extended short hairpin RNAs for HIV-1 inhibition. Nucleic Acids Res. 35, 5683-5693 (2007).
40. Sano M, Li H, Nakanishi M, Rossi JJ: Expression of long anti-HIV-1 hairpin RNAs for the generation of multiple siRNAs: advantages and limitations. Mol. Ther. 16 170-177 (2007).
41. Ter Brake O, Konstantinova P, Ceylan M, Berkhout B: Silencing of HIV-1 with RNA interference: a multiple shRNA approach. Mol. Ther. 14, 883-892 (2006).
42. Ter Brake O, Hooft KT, Liu YP. Centlivre M, Jasmijn von Eije K, Berkhout B: Lentiviral vector design for multiple shRNA expression and durable HIV-1 inhibition. Mol. Ther. (2008) (Epub ahead of print).
43. Li MJ, Kim J, Li S et al.: Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. Mol. Ther. 12, 900-909 (2005).
44. Anderson J, Banerjea A, Akkina R: Bispecific short hairpin siRNA constructs targeted to CD4, CXCR4, and CCR5 confer HIV-1 resistance. Oligonucleotides 13, 303-312 (2003).
45. Anderson J, Banerjea A, Planelles V, Akkina R: Potent suppression of HIV type 1 infection by a short hairpin anti-CXCR4 siRNA. AIDS Res. Hum. Retroviruses 19, 699-706 (2003).
46. Martinez MA, Gutiérrez A, Armand-Ugón M et al.: Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication. AIDS 16, 2385-2390 (2002):
47. Zhou N, Fang J, Mukhtar M, Acheampong E, Pomerantz RJ: Inhibition of HIV-1 fusion with small interfering RNAs targeting the chemokine coreceptor CXCR4. Gene Ther. 11, 1703-1712 (2004).
48. Liu R, Paxton WA, Choe S et al.: Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86, 367-377 (1996).
49. An DS, Donahue RE, Kamata M et al.: Stable reduction of CCR5 by RNAi through hematopoletic stem cell transplant in non-human primates. Proc. Natl Acad. Sci. USA 104, 13110-13115 (2007).
50. Ma Q, Jones D, Borghesani PR et al.: Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proc. Natl Acad. Sci. USA 95, 9448-9453 (1998).
51. + cells but markedly decreased helper cell activity in mice lacking CD4. Nature 353, 180-184 (1991).
52. Haasnoot J, Westerhout EM, Berkhout B: RNA interference against viruses: strike and counterstrike. Nat. Biotech. 25, 1435-1443 (2007).
53. Matzke M, Aufsatz W, Kanno T et al.: Genetic analysis of RNA-mediated transcriptional gene silencing. Biochim. Biophys. Acta 1677, 129-141 (2004).
54. Mette MF, Aufsatz W, van der Winden J, Matzke MA, Matzke AJ: Transcriptional silencing and promoter methylation triggered by double-stranded RNA. EMBO J. 19, 5194-5201 (2000).
55. Wassenegger M, Heimes S, Riedel L, Sanger HL: RNA-directed de novo methylation of genomic sequences in plants. Cell 76, 567-576 (1994).
56. Pal-Bhadra M, Bhadra U, Birchler JA: RNAi related mechanisms affect both transcriptional and posttranscriptional transgene silencing in Drosophila. Mol. Cell 9, 315-327 (2002).
57. Pal-Bhadra M, Leibovitch BA, Gandhi SG et al.: Heterochromatic silencing and HP1 localization in Drosophila are dependent on the RNAi machinery. Science 303, 669-672 (2004).
58. Volpe TA, Kidner C, Hall IM, Teng G, Grewal SIS, Martienssen RA: Regulation of heterochromatic silencing and histone H3 lysine-9 methylation by RNAi. Science 297, 1833-1837 (2002).
59. Grewal SI, Elgin SC: Transcription and RNA interference in the formation of heterochromatin. Nature 447, 399-406 (2007).
60. Matzke MA, Birchler JA: RNAi-mediated pathways in the nucleus. Nat. Rev. Genet. 6, 24-35 (2005).
61. Moazed D, Buhler M, Buker SM et al.: Studies on the mechanism of RNAi-dependent heterochromatin assembly. Cold Spring Harb. Symp. Quant. Biol. 71, 461-471 (2006).
62. Zofall M, Grewal SIS: RNAi-mediated heterochromatin assembly in fission yeast. Cold Spring Harb. Symp. Quant. Biol. 71, 487-496 (2006).
63. Morris KV, Chan SWL, Jacobsen SE, Looney DJ: Small interfering RNA-induced transcriptional gene silencing in human cells. Science 305, 1289-1292 (2004).
64. Castanotto D, Tommasi S, Li MJ et al.: Short hairpin RNA-directed cytosine (CpG) methylation of the RASSF1A gene promoter in HeLa cells. Mol. Ther. 12, 179-183 (2005).
65. Kim J-W, Zhang Y-H, Zero MA, Rossi JJ, Wu J: Short hairpin RNA causes the methylation of transforming growth factor-β receptor II promoter and silencing of the target gene in rat hepatic stellate cells. Biochem. Biophys. Res. Commun. 359, 292-297 (2007).
66. Park CW, Chen Z, Kren BT, Steer CJ: Double-stranded siRNA targeted to the huntingtin gene does not induce DNA methylation. Biochem. Biophys. Res. Commun. 323, 275-280 (2004).
67. Ting AH, Schuebel KE, Herman JG, Baylin SB: Short double-stranded RNA induces transcriptional gene silencing in human cancer cells in the absence of DNA methylation. Nat. Genet. 37, 906-910 (2005).
68. Han J, Kim D, Morris KV: Promoter-associated RNA is required for RNA-directed transriptional gene silencing in human cells. Proc. Natl Acad. Sci. USA 104, 12422-12427 (2007).
69. Kim DH, Villeneuve LM, Morris KV, Rossi JJ: Argonaute-1 directs siRNA-mediated transcriptional gene silencing in human cells. Nat. Struct. Mol. Biol. 13, 793-797 (2006).
70. Weinberg MS, Villeneuve LM, Ehsani A et al.: The antisense strand of small interfering RNAs directs histone methylation and transcriptional gene silencing in human cells. RNA 12, 256-262 (2006).
71. Janowski BA, Huffman KE, Schwartz JC et al.: Involvement of AGO1 and AGO2 in mammalian transcriptional silencing. Nat. Struct. Mol. Biol. 13, 787-792 (2006).
72. Jeffery L, Nakielny S: Components of the DNA methylation system of chromatin control are RNA-binding proteins. J. Biol. Chem. 279, 49479-49487 (2004).
73. Vire E, Brenner C, Deplus R et al.: The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439, 871-874 (2006).
74. Fuks F, Burgers WA, Godin N, Kasai M, Kouzarides T: Dnmt3a binds deacetylases and is recruited by a sequence-specific repressor to silence transcription. EMBO J. 20, 2536-2544 (2001).
75. Suzuki K, Shijuuku T, Fukamachi T et al.: Prolonged transriptional silencing and CpG methylation induced by dsRNAs targeted to the HIV-1 promoter region. J. RNAi Gene Silenc. 1, 66-78 (2005).
76. Weinberg MS, Morris KV: Are viral-encoded microRNAs mediating latent HIV-1 infection? DNA Cell Biol. 25, 223-231 (2006).
77. Gatignol A, Buckler-White A, Berkhout B, Jeang K-T: Characterization of a human TAR RNA-binding protein that activates the HIV-1 LTR. Science 251, 1597-1600 (1991).
78. Klase Z, Kale P, Winograd R et al.: HIV-1 TAR element is processed by Dicer to yield a viral micro-RNA involved in chromatin remodeling of the viral LTR. BMC Mol. Biol. 8, 63 (2007).
79. Ouellet DL, Plante I, Landry P et al.: Identification of functional microRNAs released through asymmetrical processing of HIV-1 TAR element. Nucleic Acids Res. 36, 2353-2365 (2008).
80. Sheridan PL, Mayall TP, Verdin E, Jones KA: Histone acetyltransferases regulate HIV-1 enhancer activity in vitro. Genes Dev. 11, 3327-3340 (1997).
81. Van Lint C, Emiliani S, Ott M, Verdin E: Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation. EMBO J. 15, 1112-1120 (1996).
82. Ylisastigui LA, Archin NMA, Lehrman GA, Bosch RJC, Margolis DMAB: Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent vital expression. AIDS 18, 1101-1108 (2004).
83. He G, Margolis DM: Counterregulation of chromatin deacetylation and histone deacetylase occupancy at the integrated promoter of human immunodeficiency virus type 1 (HIV-1) by the HIV-1 repressor YY1 and HIV-1 activator Tat. Mol. Cell. Biol. 22, 2965-2973 (2002).
84. Williams S, Chen L-F, Kwon H, Ruiz-Jarabo C, Verdin E, Greene W: NF-κB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J. 25, 139-149 (2006).
85. Jiang G, Espeseth A, Hazuda DJ, Margolis DM: c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter. J. Virol. 81, 10914-10923 (2007).
86. du Chene I, Basyuk E, Lin YL et al.: Suv39H1 and HP1γ are responsible for chromatin-mediated HIV-1 transcriptional silencing and post-integration latency. EMBO J. 26, 424-435 (2007).
87. + T lymphocytes. Nat. Med. 13, 1241-1247 (2007).
88. Waehler R, Russell SJ, Curtel DT: Engineering targeted viral vectors for gene therapy. Nat. Rev. Genet. 8, 573-587 (2007).
89. Volpers C, Kochanek S: Adenoviral vectors for gene transfer and therapy. J. Gene Med. 6, S164-S171 (2004).
90. Cohen J: Building an HIV-proof immune system. Science 317, 612-614 (2007).
91. Rossi JJ, June CH, Kohn DB: Genetic therapies against HIV. Nat. Biotech. 25, 1444-1454 (2007).
92. Hacein-Bey-Abina S, von Kalle C, Schmidt M et al.: A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 348, 255-256 (2003).
93. Hacein-Bey-Abina S, Von Kalle C, Schmidt M et al.: LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302, 415-419 (2003).
94. Kaiser J: Gene therapy: panel urges limits on X-SCID trials. Science 307, 1544a-1545a (2005).
95. Mitchell RS, Beitzel BF, Schroder ARW et al.: Retroviral DNA integration: ASLV, HIV and MLV show distinct target site preferences. PLoS Biol. 2, e234 (2004).
96. Wu X, Li Y, Crise B, Burgess SM: Transcription start regions in the human genome are favored targets for MLV integration. Science 300, 1749-1751 (2003).
97. Deichmann A, Hacein-Bey-Abina S, Schmidt M et al.: Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. J. Clin. Invest. 117, 2225-2232 (2007).
98. Bester AC, Schwartz M, Schmidt M et al.: Fragile sites are preferential targets for integrations of MLV vectors in gene therapy. Gene Ther. 13, 1057-1059 (2006).
99. Schröder AR, Shinn P, Chen H, Berry C, Ecker JR, Bushman F: HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110, 521-529 (2002).
100. + hematopoietic cells. Blood 110, 1770-1778 (2007).
101. Landau NR, Littman DR: Packaging system for rapid production of murine leukemia virus vectors with variable tropism. J. Virol. 66, 5110-5113 (1992).
102. Yu S-F, Ruden TV, Kantoff PW et al.: Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc. Natl Acad Sci. USA 83, 3194-3198 (1986).
103. Hawley RG, Covarrubias L, Hawley T, Mintz B: Handicapped retroviral vectors efficiently transduce foreign genes into hematopoietic stem cells. Proc. Natl Acad. Sci. USA 84, 2406-2410 (1987).
104. Yee J-K, Moores JC, Jony DJ, Wolff JA, Respess JG, Friedmann T: Gene expression from transcriptionally disabled retroviral vectors. Proc. Natl Acad. Sci. USA 84, 5197-5201 (1987).
105. + hematopoietic progenitor cells potently inhibits human immunodeficiency virus-1 replication. Mol. Ther. 15, 76-85 (2007).
106. Li M, Li H, Rossi JJ: RNAi in combination with a ribozyme and TAR decoy for treatment of HIV infection in hematopoietic cell gene therapy. Ann. NY Acad Sci. 1082, 172-179 (2006).
107. Qin X-E An DS, Chen ISY, Baltimore D: Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc. Natl Acad. Sci. USA 100, 183-188 (2003).
108. Yam PY, Li S, Wu J, Hu J, Zaia JA, Yee J-K: Design of HIV vectors for efficient gene delivery into human hematopoietic cells. Mol. Ther. 5, 479-484 (2002).
109. Dropulic B, Hermankova M, Pitha PM: A conditionally replicating HIV-1 vector interferes with wild-type HIV-1 replication and spread. Proc. Natl Acad. Sci. USA 93, 11103-11108 (1996).
110. Evans JT, Garcia JV: Lentivirus vector mobilization and spread by human immunodeficiency virus. Hum. Gene Ther. 11, 2331-2339 (2000).
111. Weinberger LS, Schaffer DV, Arkin AP: Theoretical design of a gene therapy to prevent AIDS but not human immunodeficiency virus type 1 infection. J. Virol. 77, 10028-10036 (2003).
112. Morris KV, Looney DJ: Characterization of human immunodeficiency virus (HIV)-2 vector mobilization by HIV-1. Hum. Gene Ther. 16, 1463-1472 (2005).
113. An DS, Morizono K, Li Q-X, Mao SH, Lu S, Chen ISY: An inducible human immunodeficiency virus type 1 (HIV-1) vector which effectively suppresses HIV-1 replication. J. Virol. 73, 7671-7677 (1999).
114. Bukovsky AA, Song JP, Naldini LL: Interaction of human immunodeficiency virus-derived vectors with wild-type virus in transduced cells. J. Virol. 73, 7087-7092 (1999).
115. Corbeau P, Wong-Staal F: Anti-HIV effects of HIV vectors. Virology 243, 268-274 (1998).
116. Levine BL, Humeau LM, Boyer J et al.: Gene transfer in humans using a conditionally replicating lentiviral vector. Proc. Natl Acad. Sci. USA 103, 17372-17377 (2006).
117. Grimm D, Streetz KL, Jopling CL et al.: Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441, 537-541 (2006).
118. Fedorov Y, Anderson EM, Birmingham A et al.: Off-target effects by siRNA can induce toxic phenotype. RNA 12, 1188-1196 (2006).
119. Klimatcheva E, Planelles V, Day SL, Fulreader F, Renda MJ, Rosenblatt J: Defective lentiviral vectors are efficiently trafficked by HIV-1 and inhibit its replication. Mol. Ther. 3, 928-939 (2001).
120. Weinberg MS, Barichievy S, Schaffer L, Han J, Morris KV: An RNA targeted to the HIV-1 LTR promoter modulates indiscriminate off-target gene activation. Nucleic Acids Res. 35(21), 7303-7312 (2007).
121. Janowski BA, Younger ST, Hardy DB, Ram R, Huffman KE, Corey DR: Activating gene expression in mammalian cells with promoter-targeted duplex RNAs. Nat. Chem. Biol. 3, 166-173 (2007).
122. Li L-C, Okino ST, Zhao H et al.: Small dsRNAs induce transcriptional activation in human cells. Proc. Natl Acad. Sci. USA 103, 17337-17342 (2006).
123. Vasudevan S, Tong Y, Steitz JA: Switching from repression to activation: microRNAs can up-regulate translation. Science 318(5858), 1931-1934 (2007).